RxDoctor Payments Data

Emily Turner, APRN

Family · Hot Springs, ARNPI 1053917310

Payments from drug & device makers

$1,136in general payments, 2019–2025

Across 60 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$380
  • Baxter Healthcare$239
  • AstraZeneca$125
  • Otsuka America Pharmaceutical, Inc.$55
  • GSK$48
  • Merck$43
  • plus $245 from 10 others

What the payments were for

  • Food & beverage$89779%
  • Other$23921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,136 in reported general payments places this provider in the 70th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$940
Medicare patients
21
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$29,242
OzempicSemaglutide27$25,485
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,696
TrulicityDulaglutide15$11,316
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$10,084
Aimovig AutoinjectorErenumab-Aooe12$8,883
MyrbetriqMirabegron14$8,506
Combivent RespimatIpratropium/Albuterol Sulfate16$7,526
Gabapentin174$3,236
Ventolin HfaAlbuterol Sulfate47$2,619
Albuterol Sulfate HfaAlbuterol Sulfate111$2,610
Omeprazole250$2,530
Levothyroxine Sodium215$2,070
Lisinopril222$1,318
Potassium Chloride79$1,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$29$40,55741 claims
GSKTrelegy Ellipta$48$19,69621 claims
Boehringer IngelheimCombivent Respimat$34$7,52616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,103 family providers in Arkansas.

Other family in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →